<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139373</url>
  </required_header>
  <id_info>
    <org_study_id>RBM0323</org_study_id>
    <nct_id>NCT00139373</nct_id>
  </id_info>
  <brief_title>Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy</brief_title>
  <official_title>Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <brief_summary>
    <textblock>
      The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction
      of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy
      (PSP), a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and
      cholinergic systems, in particular in the Meynert basalis nucleus. This could participate in
      the occurrence of the distractibility in these patients. The aim of this study is to evaluate
      the effect of the donepezil, an anticholinesterase, on the distractibility in PSP patients,
      by using oculomotor and neuropsychological assessments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Supranuclear Palsy, Progressive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with PSP

          -  Age &gt; 30 years old

          -  Disease duration &lt; 5 years

          -  Mini mental state (MMS) &gt; 24

          -  Antisaccades %: 40-80%

        Exclusion Criteria:

          -  Other parkinsonian syndromes

          -  MMS &lt; 24
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Gaymard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM-U679</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand Gaymard, MD, PhD</last_name>
    <phone>33-142162218</phone>
    <email>gaymard@ccr.jussieu.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Rivaud-Pechoux, PhD</last_name>
    <phone>33-142162218</phone>
    <email>rivaud@ccr.jussieu.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Laure Welter, MD</last_name>
      <phone>33-42161950</phone>
      <email>marie-laure.welter@psl.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bertrand Gaymard, MD, PhD</last_name>
      <phone>33-142162218</phone>
      <email>gaymard@ccr.jussieu.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bertrand Gaymard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>September 12, 2007</last_update_submitted>
  <last_update_submitted_qc>September 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2007</last_update_posted>
  <keyword>Progressive supranuclear palsy</keyword>
  <keyword>Frontal lobe</keyword>
  <keyword>Oculomotor testing</keyword>
  <keyword>Neuropsychological scores</keyword>
  <keyword>Motor disability (UPDRS)</keyword>
  <keyword>Distractibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

